

Genotype and treatment initiation in clinically unclassified children with MEFV variants: a retrospective cohort study

Pelin Esmeray Şenol

pesmeray87@hotmail.com

Mersin Şehir Eğitim ve Araştırma Hastanesi

Nuran Belder

Gazi University

Çisem Yıldız

Gazi University

Nihal Karaçayır

Gazi University

Merve Kutlar Tanıdır

Gazi University

Batuhan Küçükali

Gazi University

Deniz Gezgin Yıldırım

Gazi University

Sevcan Bakkaloğlu

Gazi University

Research Article

Keywords: Familial Mediterranean fever, MEFV, Heterozygous carrier, Colchicine, Autoinflammation, Children

Posted Date: October 14th, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-11167640/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations:

No competing interests reported.

Tables are available in the Supplementary Files section.

Genotype and treatment initiation in clinically unclassified children with *MEFV* variants: a retrospective cohort study

Pelin ESMERAY ŞENOL¹, Nuran BELDER², Çisem YILDIZ², Nihal KARAÇAYIR², Merve KUTLAR TANIDIR², Batuhan KÜÇÜKALİ², Deniz GEZGİN YILDIRIM², Sevcan A. BAKKALOĞLU²

Department of Pediatric Rheumatology, Mersin City Training and Research Hospital, Mersin, Turkey.¹

Department of Pediatric Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.²

Pelin Esmeray Şenol, pesmeray87@hotmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0002-9493-9355>

Nuran Belder, nuran.belder@gmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0001-6058-5037>

Çisem Yıldız, dr.cisemyildirim@hotmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0002-6901-9944>

Nihal Karaçayır, nihal_karacayir@hotmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0001-5038-7539>

Merve Kutlar Tanıdır, merve.kutlar@gmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0003-0218-3130>

Batuhan Küçükali, batuhankucukali@gmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0002-4268-8603>

Deniz Gezgin Yıldırım, gezgindeniz@gmail.com, +903122025132, ORCID iD <https://orcid.org/0000-0002-4823-2076>

Sevcan A. Bakkaloğlu, sevcan@gazi.edu.tr, +903122025132, ORCID iD <https://orcid.org/0000-0001-6530-9672>

Corresponding author

Pelin Esmeray Şenol, MD

Mersin City Training and Research Hospital

Department of Pediatric Rheumatology

Mersin, Turkey, 21000

e-mail: pesmeray87@hotmail.com

Phone: +903242251000

Fax: +903242251000

Number of pages: 10

Number of tables: 4

Number of figures: 2

Abstract

Purpose Management of children with *MEFV* variants who do not fulfil clinical criteria for familial Mediterranean fever (FMF) at presentation is controversial. We described their clinical course and baseline factors associated with later treatment initiation.

Methods This retrospective cohort study included 116 children (<18 years) with at least one *MEFV* variant who did not fulfil the Eurofever/PRINTO criteria for FMF at first evaluation between 2015 and 2024. Children were classified as treated (n = 61) or followed without treatment (n = 55). Time to treatment initiation was analysed with the Kaplan–Meier method. Groups were compared with non-parametric, Fisher's exact and log-rank tests.

Results The median age at first visit was 8.0 [4.8–11.2] years, and the median follow-up was 2.5 [1.2–5.1] years. Treatment was started in 61 children (52.6%) at a median of 0.6 [0.3–1.1] years after the first evaluation. Among the 104 children carrying a single variant, 52 (50.0%) were treated. Their cumulative probability of treatment initiation was 37.4%, 49.1% and 57.0% at 1, 2 and 5 years. All six children with M694V/E148Q were treated (P = 0.028), compared with 5/17 (29.4%) children with isolated E148Q (P = 0.064). Baseline CRP was modestly higher in treated children (4.8 vs 3.0 mg/L, P = 0.014), whereas ESR and family history were not.

Conclusion Half of the children with a single *MEFV* variant who did not meet FMF criteria at presentation were started on treatment, mostly within the first year. These children warrant structured longitudinal follow-up. Genotype-specific findings involved small subgroups and require prospective validation.

Keywords Familial Mediterranean fever · *MEFV* · Heterozygous carrier · Colchicine · Autoinflammation · Children

What is Known:

- Many children with *MEFV* variants do not fulfil FMF classification criteria at first evaluation, and their management is uncertain.
- Isolated E148Q heterozygosity rarely causes clinically significant FMF.

What is New:

- Half of clinically unclassified children with a single *MEFV* variant were started on colchicine, mostly within the first year.
- Baseline acute-phase reactants and family history did not reliably identify children who later required treatment.

Abbreviations

CI	Confidence interval
CRP	C-reactive protein
ESR	Erythrocyte sedimentation rate
EULAR	European Alliance of Associations for Rheumatology
FMF	Familial Mediterranean fever
IL-1	Interleukin-1
INSAID	International Study Group for Systemic Autoinflammatory Diseases
IQR	Interquartile range
PRoS	Paediatric Rheumatology European Society
PRINTO	Paediatric Rheumatology International Trials Organisation

Introduction

78 Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease.
79 It is caused by variants in the *MEFV* gene, which encodes pyrin, and is characterised by
80 recurrent, self-limiting attacks of fever with serositis or arthritis. AA amyloidosis is its most
81 serious complication [1–3]. FMF is classically an autosomal recessive disease. However, a
82 substantial proportion of symptomatic patients carry only a single detectable *MEFV* variant.
83 Incomplete penetrance, variable expressivity and an apparent dominant pattern of inheritance are
84 now well recognised [2, 4]. The pathogenicity of several common variants also remains
85 uncertain. Nearly a third are classified as variants of uncertain significance by
86 INSAID/INFEVERS, and E148Q has long been debated as either a benign polymorphism or a
87 low-penetrance disease-causing allele [5, 6]. The 2019 Eurofever/PRINTO classification criteria
88 were an important step towards standardisation [7]. In real-world practice, however, a sizeable
89 group of genetically positive patients still cannot be classified [8].
90 Widespread genetic testing has produced a growing population of children who carry an *MEFV*
91 variant but do not fulfil clinical FMF criteria at evaluation. In these children, complaints may be
92 non-specific, attacks may be infrequent or afebrile, or testing may have been prompted by family
93 history [9, 10]. The clinical significance of this finding remains uncertain. The 2024
94 EULAR/PReS recommendations aim for complete control of clinical and subclinical
95 inflammation with lifelong colchicine in established FMF [1, 11]. However, they do not address
96 asymptomatic or oligosymptomatic carriers, and there is no consensus on how these children
97 should be monitored or treated [1, 4].
98 This uncertainty has practical consequences. Over-treatment exposes children to lifelong
99 colchicine without clear benefit. Under-recognition, in contrast, may delay the control of
100 subclinical inflammation and, rarely, lead to amyloidosis [3]. We therefore reviewed a single-
101 centre paediatric cohort of children with *MEFV* variants who did not meet clinical FMF criteria at

presentation. We aimed to determine the proportion of children subsequently started on treatment, the time to treatment initiation and the baseline features associated with this outcome. We focused particularly on children carrying a single variant, the group in whom management is least clear.

Materials and methods

Study population

We performed a retrospective cohort study at the paediatric rheumatology clinic of Gazi University Faculty of Medicine. We identified all children (<18 years at first visit) evaluated between 2015 and 2024 in whom *MEFV* sequencing showed at least one variant. Children were eligible if they did not fulfil the Eurofever/PRINTO classification criteria for FMF at first evaluation [7]. Eurofever/PRINTO criteria were considered unmet at first evaluation when complaints had not yet shown a recurrent, stereotyped episodic pattern and when joint complaints consisted of arthralgia without objective arthritis. Children meeting clinical FMF criteria at presentation were excluded. Children with an alternative autoinflammatory or rheumatic diagnosis explaining their symptoms were also excluded. In total, 116 children were included. The index date was the first paediatric rheumatology visit at which the *MEFV* result was available. The reason for referral was classified as symptomatic (non-specific complaints) or family screening.

MEFV analysis was performed by Sanger sequencing of exons 2, 3, 5 and 10, which contain the great majority of known *MEFV* variants. Variants are described using conventional protein-level abbreviations (e.g. M694V, E148Q). Variant phase (cis/trans) was not determined by parental testing. Genotypes with two variants are therefore described as 'dual-variant' rather than 'compound heterozygous' or 'biallelic' throughout this manuscript.

Data collection and outcome

From electronic and paper records, we extracted demographic data, presenting complaints, family history of rheumatic or autoinflammatory disease, *MEFV* genotype and laboratory parameters at presentation and at the last visit. Laboratory parameters included haemoglobin, white-cell and platelet counts, ESR and CRP. Genotypes were grouped as single-variant (heterozygous) or dual-variant. We also examined four overlapping groups. These were M694V carriers (heterozygous or dual-variant), exon-10 variant carriers (M694V, M680I, V726A, K695R, R761H or A744S), the M694V/E148Q dual-variant genotype and isolated E148Q heterozygosity.

The primary outcome was treatment initiation during follow-up. Treatment decisions were made by the treating paediatric rheumatologist. Colchicine was initiated when a child developed recurrent, stereotyped, self-limiting FMF-compatible attacks (fever, abdominal, chest or joint involvement lasting 12–72 h) and/or persistent elevation of acute-phase reactants between attacks after exclusion of alternative causes. Time to treatment initiation was defined as the interval, in years, between the index date and the start of treatment. For treated children, we recorded the clinical features at treatment initiation, the number of attacks in the preceding 6 months and the attack duration. Attack duration was recorded in calendar days. An attack lasting up to 72 h may therefore span four calendar days. Children were classified as treated (n = 61) or followed without treatment (n = 55). Of the treated children, 60 received colchicine alone. One child also received an IL-1 inhibitor because of an incomplete response to colchicine.

Statistical analysis

Continuous variables were tested for normality with the Shapiro–Wilk test. As they were not normally distributed, they are presented as median [IQR] and compared with the Mann–Whitney U test. Categorical variables are presented as counts (%) and compared with Fisher's exact test.

Exact (Clopper–Pearson) 95% CIs were calculated for treatment proportions. Time to treatment initiation was analysed with the Kaplan–Meier method, and untreated children were censored at their last visit. One treated child with a missing treatment date was excluded from the time-to-event analyses (n = 115). Treatment-free survival was compared between genotype groups with the log-rank test. Two sensitivity analyses were performed. The first excluded children referred for family screening, and the second excluded children followed for less than 1 year. Genotype subgroup analyses were exploratory, and P-values are reported without correction for multiple comparisons. A two-sided $P < 0.05$ was considered significant. Analyses were performed with SPSS version 21.0 (IBM Corp., Armonk, NY, USA).

Results

The cohort comprised 116 children. The median age at analysis was 12.7 [9.7–17.4] years, and the median age at first visit was 8.0 [4.8–11.2] years. The median follow-up was 2.5 [1.2–5.1] years, with a range of 0.1 to 7.6 years (Table 1). The most frequent presenting complaints were abdominal pain (56.9%), fever (36.2%), and joint complaints (20.7%); 8.6% were referred for family history alone. A family history of rheumatic or autoinflammatory disease was present in 74 children (63.8%), most commonly FMF. Five families (4.3%) reported FMF with amyloidosis. A single variant was detected in 104 children (89.7%) and two variants in 12 (10.3%). M694V/– was the most frequent genotype (47.4%), followed by V726A/– (15.5%) and E148Q/– (14.7%). During follow-up, treatment was initiated in 61 children (52.6%). The remaining 55 children (47.4%) were followed without treatment. Their median follow-up was 2.3 [0.9–4.5] years, and 29 of them were followed for at least 2 years. All untreated children were asymptomatic at the last visit.

Among treated children, the median time from the first evaluation to treatment initiation was 0.6 [0.3–1.1] years. Treatment was usually started after the first or second attack observed after the index visit (median 1 [1–2]). Clinical features at treatment initiation are shown in Table 3. Fever was present in 34 children (56.7%), abdominal pain in 35 (58.3%), joint involvement in 14 (23.3%) and chest pain in 4 (6.7%). Three children (5.0%) were treated for persistently elevated acute-phase reactants alone. The median number of attacks was 3 [2–6] per 6 months. The median attack duration was 3 [2–4] days, and attacks lasted 3 days or less in 44/60 children (73.3%).

Treatment initiation by genotype group is shown in Figure 1. Among the 104 single-variant carriers, 52 (50.0%, 95% CI 40.0–60.0%) were treated. The treatment rate was 29/55 (52.7%) in children with M694V/–. Among the 12 dual-variant carriers, 9 (75.0%) were treated ($P = 0.131$). All six children with M694V/E148Q were treated (100%, 95% CI 54.1–100%, $P = 0.028$). Isolated E148Q heterozygosity showed a numerically lower treatment rate (5/17, 29.4%, $P = 0.064$). Treatment initiation was not associated with carriage of an exon-10 variant (54/97, 55.7%, $P = 0.208$) or of M694V (36/63, 57.1%, $P = 0.351$).

In the time-to-event analysis, the cumulative probability of treatment initiation for the whole cohort was 40.8% at 1 year, 52.6% at 2 years and 59.9% at 5 years. The corresponding estimates for single-variant carriers were 37.4%, 49.1% and 57.0% (Figure 2A). Treatment-free survival was longer in single-variant than in dual-variant carriers (log-rank $P = 0.010$). In the exploratory comparison, treatment-free survival was shorter in children with M694V/E148Q than in the rest of the cohort (log-rank $P = 0.001$) (Figure 2B).

The results were similar in both sensitivity analyses (Online Resource 1). Of the 10 children referred for family screening, 3 were treated. After their exclusion, 58/106 children (54.7%) were treated. Among the 96 children followed for at least 1 year, 56 (58.3%) were treated. In this

group, the cumulative probability of treatment initiation was 41.1%, 52.8% and 60.1% at 1, 2 and 5 years.

Baseline CRP was higher in the treated group (4.8 [2.8–17.5] vs 3.0 [1.9–6.6] mg/L, $P = 0.014$).

Baseline ESR did not differ significantly between groups (14.0 [9.0–36.0] vs 13.0 [8.5–21.0] mm/h, $P = 0.123$) (Table 2). At the last visit, ESR and CRP were comparable between groups and within the normal range. Baseline haematological indices, age at presentation and follow-up duration did not differ between groups. A positive family history was not associated with treatment initiation ($P = 0.334$).

Discussion

In this cohort, half of the children who carried a single *MEFV* variant and did not meet FMF criteria at presentation were subsequently started on treatment. Overall, 52.6% of the cohort was treated, at a median of 0.6 years after the first evaluation. These findings indicate that a single *MEFV* variant can be associated with a clinically relevant phenotype that emerges after the initial assessment. This is consistent with previous reports of symptomatic heterozygous carriers [4, 5, 12]. In practice, these children should not be discharged after a single evaluation. Structured longitudinal follow-up appears warranted, particularly when complaints recur or evolve towards an FMF-compatible pattern.

The high treatment rate among single-variant carriers is the main finding of this study. FMF is classically considered an autosomal recessive disease, and heterozygous carriers are often regarded as unaffected. In our cohort, however, the treatment rate in children with M694V/– (52.7%) was similar to that of the whole cohort. This is consistent with the view that heterozygosity for a pathogenic exon-10 variant may contribute to a clinically relevant phenotype in some children [2, 4, 5]. Most treatment decisions were made within the first year. The

cumulative probability curves showed that new treatment decisions continued beyond this point, although at a slower rate. A single early assessment may therefore not be sufficient.

As expected, treatment rates were higher in dual-variant carriers. All six children with M694V/E148Q were treated. M694V is associated with the most severe disease course, including earlier onset, more frequent attacks and a higher risk of amyloidosis and colchicine resistance [3, 13]. E148Q is thought to modify the phenotype when combined with a more pathogenic variant [14, 15]. In contrast, only 5 of 17 children with isolated E148Q were treated. This difference did not reach statistical significance and was based on a small group. It is nevertheless consistent with paediatric data indicating that E148Q alone rarely causes clinically significant FMF [14–17].

The genotype-specific comparisons involved small subgroups. Treating physicians were also aware of each child's genotype, which may have influenced their decisions. These results should therefore be regarded as exploratory.

Two features that are often used in clinical practice were weak predictors of treatment in this cohort. Baseline CRP was only modestly higher in treated children, and ESR did not differ between groups. At the last visit, both markers were similar in the two groups. Because laboratory sampling was not standardised, these data do not allow firm conclusions about intermittent or subclinical inflammation. More sensitive markers, such as S100A12, may be useful in this population [18]. Family history was present in 63.8% of the cohort but was not associated with treatment initiation. Family history remains important for identifying at-risk families and the risk of amyloidosis. However, it does not appear to justify pre-emptive treatment on its own. Taken together, these findings suggest that treatment decisions should be based on genotype combined with clinical follow-up rather than on family history or isolated laboratory markers [1, 4, 7].

This cohort also illustrates the diagnostic difficulty in this group. Many children presented with vague or afebrile symptoms. This is consistent with the recognition that FMF does not always present classically. Even useful classification criteria leave a group of genetically positive children who cannot be classified [7–9, 19–21]. Colchicine is well tolerated across paediatric age groups, including young children. IL-1 inhibitors are generally reserved for colchicine resistance or intolerance [22–26]. The main disadvantage of pre-emptive treatment is therefore the burden of unnecessary lifelong therapy rather than toxicity. Recent evidence shows that colchicine can be safely withdrawn in some carriers [12]. This further underlines the need to identify prospectively which children require treatment.

Limitations

This study has several limitations. It was a retrospective, single-centre study without a fixed schedule for laboratory testing. The sample size limited the statistical power for less common genotypes and precluded multivariable modelling. Genotype subgroup comparisons were exploratory and were not corrected for multiple testing. Treatment criteria were applied by the treating physicians and were not prospectively standardised. Physicians were also aware of each child's genotype, which may have influenced treatment decisions. Treatment initiation should therefore not be regarded as a purely objective marker of disease progression. Time to treatment was reconstructed from records and depended on visit frequency and documentation. Follow-up was short relative to the latency of amyloidosis. Finally, as this was a referral cohort, our findings may not be generalisable to other settings. Prospective multicentre studies with predefined treatment criteria and longer follow-up are needed to confirm these findings.

Conclusion

Half of the children with a single *MEFV* variant who did not meet clinical FMF criteria at presentation were started on treatment during follow-up, mostly within the first year. These children therefore require structured longitudinal follow-up rather than discharge after a single assessment. In exploratory analyses, all children with M694V/E148Q were treated, whereas isolated E148Q heterozygosity showed a lower treatment rate. Family history and baseline acute-phase reactants were not consistently associated with treatment initiation. These findings require validation in prospective cohorts with predefined diagnostic and treatment criteria.

Statements and Declarations

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests The authors have no relevant financial or non-financial interests to disclose.

Author contributions Pelin Esmeray Şenol: conceptualisation, data curation, formal analysis, methodology, writing – original draft. Nuran Belder, Çisem Yıldız, Nihal Karaçayır, Merve Kutlar Tanıdır and Batuhan Küçükali: data curation, investigation. Deniz Gezgin Yıldırım: methodology, supervision. Sevcan A. Bakkaloğlu: supervision, writing – review and editing. All authors read and approved the final manuscript.

Ethics approval The study was approved by the Ethics Committee of Gazi University (approval no. 2025-1812, decision of the 16th session dated 21 October 2025). It was conducted in accordance with the Declaration of Helsinki.

Consent to participate Individual informed consent was waived by the Ethics Committee because of the retrospective design.

Consent to publish Not applicable. The manuscript contains no identifiable individual data.

Data availability The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. Ozen S, Sağ E, Oton T, et al (2025) EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update. *Ann Rheum Dis* 84:899–909. <https://doi.org/10.1016/j.ard.2025.01.028>
2. Kacar M, Pathak S, Savic S (2019) Hereditary systemic autoinflammatory diseases and Schnitzler's syndrome. *Rheumatology (Oxford)* 58:vi31–vi43. <https://doi.org/10.1093/rheumatology/kez448>
3. Lancieri M, Bustaffa M, Palmeri S, Prigione I, Penco F, Papa R, Volpi S, Caorsi R, Gattorno M (2023) An update on familial Mediterranean fever. *Int J Mol Sci* 24:9584. <https://doi.org/10.3390/ijms24119584>
4. Ben-Chetrit E (2024) Old paradigms and new concepts in familial Mediterranean fever (FMF): an update 2023. *Rheumatology (Oxford)* 63:309–318. <https://doi.org/10.1093/rheumatology/kead439>
5. Ben-Chetrit E, Touitou I (2024) The significance of carrying *MEFV* variants in symptomatic and asymptomatic individuals. *Clin Genet* 106:217–223. <https://doi.org/10.1111/cge.14566>
6. Van Gijn ME, Ceccherini I, Shinar Y, et al (2018) New workflow for classification of genetic variants' pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID). *J Med Genet* 55:530–537. <https://doi.org/10.1136/jmedgenet-2017-105216>

305 7. Gattorno M, Hofer M, Federici S, et al (2019) Classification criteria for autoinflammatory
306 recurrent fevers. *Ann Rheum Dis* 78:1025–1032. [https://doi.org/10.1136/annrheumdis-2019-](https://doi.org/10.1136/annrheumdis-2019-215048)
307 215048

308 8. Bustaffa M, Koné-Paut I, Ozen S, et al (2022) The impact of the Eurofever criteria and the new
309 InFevers *MEFV* classification in real life: results from a large international FMF cohort. *Semin*
310 *Arthritis Rheum* 52:151957. <https://doi.org/10.1016/j.semarthrit.2022.151957>

311 9. Arık SD, Kayaalp GK, Guliyeva V, et al (2023) Not easy-peasy to diagnose: familial
312 Mediterranean fever unaccompanied by fever. *Eur J Pediatr* 182:3983–3988.
313 <https://doi.org/10.1007/s00431-023-05061-6>

314 10. Cam V, Cingoz E, Ercan Emreol H, et al (2026) Before calling it FMF: *MEFV* variants of
315 uncertain significance in autoinflammatory disease. *Rheumatology (Oxford)* 65:keag252.
316 <https://doi.org/10.1093/rheumatology/keag252>

317 11. El-Shanti H (2025) Guided management of familial Mediterranean fever. *Nat Rev Rheumatol*
318 21:578–579. <https://doi.org/10.1038/s41584-025-01281-2>

319 12. Cam V, Unal D, Sag E, et al (2025) Re-evaluation of *MEFV* carriers previously diagnosed
320 with FMF: a colchicine discontinuation study. *Rheumatology (Oxford)* 64:5726–5732.
321 <https://doi.org/10.1093/rheumatology/keaf340>

322 13. Öztürk K, Coşkun T, Bağlan E, et al (2022) Real-life data from the largest pediatric familial
323 Mediterranean fever cohort. *Front Pediatr* 9:805919. <https://doi.org/10.3389/fped.2021.805919>


324 14. Fujimoto K, Hidaka Y, Koga T, Kaieda S, Yamasaki S, Nakashima M, Hoshino T,
325 Yamamoto K, Nishikomori R, Ida H (2021) *MEFV* E148Q variant is more associated with
326 familial Mediterranean fever when combined with other non-exon 10 *MEFV* variants in Japanese
327 patients with recurrent fever. *Mod Rheumatol* 31:1208–1214.
328 <https://doi.org/10.1080/14397595.2021.1880534>

- 329 15. Orouk Awaad E, Khoury L, van Straalen JW, Miller-Barmak A, Gazitt T, Haddad-Haloun J,
330 Brik R, Hamad Saied M (2024) E148Q variant: a familial Mediterranean fever-causing mutation
331 or a sequence variant?. *Eur J Pediatr* 183:4499–4506. [https://doi.org/10.1007/s00431-024-05690-](https://doi.org/10.1007/s00431-024-05690-5)
332 5
- 333 16. Tirosh I, Yacobi Y, Vivante A, Barel O, Ben-Moshe Y, Erez Granat O, Spielman S, Semo Oz
334 R, Shinar Y, Gerstein M (2021) Clinical significance of E148Q heterozygous variant in paediatric
335 familial Mediterranean fever. *Rheumatology (Oxford)* 60:5447–5451.
336 <https://doi.org/10.1093/rheumatology/keab128>
- 337 17. Tanatar A, Sönmez HE, Sözeri B, Aktay Ayaz N (2021) Comment on: Clinical significance
338 of E148Q heterozygous variant in paediatric familial Mediterranean fever. *Rheumatology*
339 (Oxford) 60:e294–e295. <https://doi.org/10.1093/rheumatology/keab205>
- 340 18. Türkmenoğlu Y, Güney E, Bezen D, İrdem A, Ertürk B, Dursun H (2021) Evaluation of
341 S100A12 protein levels in children with familial Mediterranean fever. *Turk J Med Sci* 51:1396–
342 1405. <https://doi.org/10.3906/sag-2009-187>
- 343 19. Tanatar A, Sönmez HE, Karadağ ŞG, Çakmak F, Çakan M, Demir F, Sözeri B, Ayaz NA
344 (2020) Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO
345 classification criteria for familial Mediterranean fever in a referral center. *Rheumatol Int* 40:21–
346 27. <https://doi.org/10.1007/s00296-019-04463-w>
- 347 20. Sag E, Demirel D, Demir S, Atalay E, Akca U, Bilginer Y, Ozen S (2020) Performance of the
348 new 'Eurofever/PRINTO classification criteria' in FMF patients. *Semin Arthritis Rheum* 50:172–
349 175. <https://doi.org/10.1016/j.semarthrit.2019.08.004>
- 350 21. Çağlayan Ş, Mardinoğlu G, Yazar MH, et al (2023) The assessment of autoinflammatory
351 disease classification criteria (Eurofever/PRINTO) in a real-life cohort. *Clin Rheumatol* 42:1645–
352 1653. <https://doi.org/10.1007/s10067-023-06557-0>

22. Erkilet HK, Gezgin Yıldırım D, Esmeray P, Söylemezoğlu O (2023) Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever. *Pediatr Int* 65:e15588. <https://doi.org/10.1111/ped.15588>
23. Poddighe D, Romano M, Garcia-Bournissen F, Demirkaya E (2022) Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease. *Br J Clin Pharmacol* 88:2484–2499. <https://doi.org/10.1111/bcp.15149>
24. Ozen S, Sag E, Ben-Chetrit E, et al (2021) Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. *Rheumatology (Oxford)* 60:3799–3808. <https://doi.org/10.1093/rheumatology/keaa863>
25. Sener S, Cam V, Batu ED, Kasap Cuceoglu M, Balik Z, Aliyev E, Bayindir Y, Basaran O, Bilginer Y, Ozen S (2023) Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever. *Rheumatology (Oxford)* 62:3700–3705. <https://doi.org/10.1093/rheumatology/kead128>
26. Goldberg O, Levinsky Y, Peled O, Koren G, Harel L, Amarilyo G (2019) Age dependent safety and efficacy of colchicine treatment for familial Mediterranean fever in children. *Semin Arthritis Rheum* 49:459–463. <https://doi.org/10.1016/j.semarthrit.2019.05.011>

Figure legends


Fig. 1 Treatment initiation by *MEFV* genotype group. Bars show the proportion of children in each genotype group who were started on treatment during follow-up, with exact (Clopper–Pearson) 95% CIs. Numbers to the right of each bar show treated/total (%) and the Fisher's exact P-value for that group compared with the remainder of the cohort. Genotype groups are not mutually exclusive. P-values are uncorrected




Fisher's exact test vs remainder of cohort; uncorrected P-values

Fig. 2 Treatment-free survival by *MEFV* genotype. Kaplan–Meier estimates of the probability of remaining without treatment after the first evaluation (n = 115). (A) Single-variant (n = 103) vs dual-variant (n = 12) carriers, log-rank P = 0.010. (B) M694V/E148Q (n = 6) vs all other genotypes (n = 109), log-rank P = 0.001 (exploratory comparison). Numbers of patients at risk are shown below each panel

Treatment-free survival by *MEFV* genotype



At risk								
Single-variant	103	55	34	28	22	13	7	0
Dual-variant	12	2	1	1	1	0	0	0



At risk								
Other genotypes	109	56	35	29	23	13	7	0
M694V/E148Q	6	1	0	0	0	0	0	0

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [MEFVtables23.09.2026.docx](#)
- [MEFVSupplementaryTable23.09.2026.docx](#)